Arecor Therapeutics PLC - Cambridgeshire, England-based biopharmaceutical company - Announces the orderly cessation of operations within the Tetris Pharma subsidiary, and a mutual agreement with Xeris BioPharma Holdings Inc to return the group’s rights to medication Ogluo. Forms part of the group’s strategic review. This concludes that rising supply chain costs and fixed selling prices have significantly reduced margins for Ogluo. In addition, the 2025 revenue outlook for non-Ogluo sales has been materially reduced in light of a partner losing a key NHS tender, materially reducing 2025 revenues for non-Ogluo products. The strategic decision to cease Tetris Pharma operations will enable the group to focus its efforts and resources on opportunities that offer ‘higher potential for value creation.’

Current stock price: 60.00 pence, down 19% in London on Friday

12-month change: down 64%

Copyright 2025 Alliance News Ltd. All Rights Reserved.